Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Barnett

Orthopaedic Surgery Orange, CA Medical Doctor

NPI 1750378030 CMS profile 261149

280 S Main St, Orange, CA 92868

Open in the dashboard

General payments

$796,751

235 records reported · program years 2019–2025

Research payments

$7,367

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$385,585 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Steven Barnett of Orange, CA is reported in the CMS Open Payments database as having received $796,751 across 235 general payments and $7,367 in research payments paid to them. Separately, studies naming them as principal investigator received $385,585 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $164,358 21
2024 General $133,801 22
2023 General $71,972 49
2022 General $256,139 31
2021 General $86,663 65
2020 General $34,116 21
2020 Research $7,367 3
2019 General $49,701 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Barnett
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Steven Barnett were reported at $164,358. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Steven Barnett Orthopaedic Surgery median Middle half National median
2019 $49,701 $644 $140–$2,844 $163
2020 $34,116 $312 $75–$1,860 $114
2021 $86,663 $520 $117–$2,495 $132
2022 $256,139 $598 $128–$2,731 $149
2023 $71,972 $461 $128–$2,264 $160
2024 $133,801 $497 $134–$2,475 $164
2025 $164,358 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Products, Inc. $554,584 92 payments
  2. OMNIlife science, Inc $136,714 63 payments
  3. Medical Device Business Services, Inc. $54,733 38 payments
  4. Corin USA $46,843 23 payments
  5. Zimmer Biomet Holdings, Inc. $2,464 3 payments
  6. DePuy Synthes Sales Inc. $847 10 payments
  7. Smith+Nephew, Inc. $248 2 payments
  8. Pacira Pharmaceuticals Incorporated $126 1 payment
  9. Engage Uni, LLC $114 1 payment
  10. Medacta USA, Inc. $59 1 payment
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $553,868 25 payments
  2. Consulting Fee $216,780 79 payments
  3. Travel and Lodging $18,745 40 payments
  4. Food and Beverage $7,243 90 payments
  5. Gift $114 1 payment
Products named General payments · program years 2019–2025
  1. ATTUNE Ortho-Knee $593,508 114 payments
  2. OMNIBotics 3.0 Technology - Knees $36,597 12 payments
  3. OMNIBotics 3.0 Implants $17,658 15 payments
  4. Metafix Collared $8,967 1 payment
  5. ATTUNE Ortho-Knee $8,757 7 payments
  6. Velys $6,202 3 payments
  7. ACTIS $6,143 2 payments
  8. PINNACLE $6,143 2 payments
  9. Persona $2,400 1 payment
  10. NexGen $2,400 1 payment
  11. Other $3,370 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. OMNIlife science, Inc $7,367 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

319

Median for Orthopaedic Surgery: 30

Drug cost

$1,811

Median for Orthopaedic Surgery: $176

Branded share of claims

9.7%

Median for Orthopaedic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 31 $397
Celecoxib Generic 11 $300
Methocarbamol Generic 21 $229
Amoxicillin Generic 119 $211
Oxycodone Hcl Generic 28 $194
Diclofenac Sodium Generic 21 $142
Baclofen Generic 18 $111
Gabapentin Generic 14 $84
Clindamycin Hcl Generic 19 $69
Meloxicam Generic 23 $38

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,233 Part D prescribers listed as Orthopaedic Surgery; they describe a distribution and say nothing about conduct.

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record